Trimipramine and maprotiline: antidepressant, anxiolytic, and cardiotoxic comparison.
A 5-week placebo washout comparison of trimipramine 150 mg/day and maprotiline 150 mg/day was carried out in 15 male and 24 female patients with unipolar major affective disorder. There were no significant differences between the two groups in age, sex, weight, height, or vital signs. Both groups showed significant improvement over time, with no difference between the groups on the Severity and Improvement factors of the Clinical Global Impression scale, on the total and factor subscales of the Hamilton Depression Rating Scale, and on the Anxiety Status Inventory. The maprotiline group showed a greater increase in weight over the study period than did the trimipramine group. There was a significant lowering of systolic blood pressure in the trimipramine group only and a significant and linear increase in pulse rate by Week 3 in the maprotiline group. Analysis of ECG showed that the atrial rates were significantly increased in the maprotiline group (p less than .002) but not in the trimipramine group. Trimipramine had significantly fewer anticholinergic, neurologic, and cardiovascular adverse effects than maprotiline.
Pecknold
J C
JC
Familamiri
P
P
McClure
D J
DJ
Elie
R
R
Chang
H
H
D000328:Adult; D000553:Ambulatory Care; D000873:Anthracenes / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003984:Dibenzazepines / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales; D011674:Pulse / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D014299:Trimipramine / Q000009:adverse effects / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
D000873:Anthracenes; D014151:Anti-Anxiety Agents; D003984:Dibenzazepines; D008376:Maprotiline; D014299:Trimipramine